HR-8053-119
Referred to the House Committee on Financial Services.
Sponsored by Stephen Lynch (D-MA)
What it does
This bill would amend the Defense Production Act of 1950 to require the Defense Production Act Committee to meet at least twice per year, authorize its chairperson to create additional subcommittees, and formally establish a Subcommittee on Emerging Technology. That subcommittee would analyze how technologies such as artificial intelligence, biotechnology, quantum computing, semiconductors, and space technologies affect national defense needs and supply chains. The bill would also require the subcommittee to submit a report to Congress within 18 months evaluating the potential benefits, drawbacks, and costs of creating a strategic reserve of critical biomanufacturing materials.
Who benefits
Defense-oriented technology companies in sectors like semiconductors, AI, and biotechnology that may gain visibility and potential future procurement or policy support. Federal agencies involved in defense supply chain planning. Biomanufacturing firms that could benefit from a future strategic reserve program. Academic and research institutions working on emerging technologies relevant to national defense. Domestic manufacturers who could gain competitive advantage if supply chain gaps identified by the subcommittee lead to policy action.
Who is hurt
Foreign technology suppliers and manufacturers who could face increased scrutiny or reduced access to U.S. defense-related contracts if the subcommittee's findings lead to domestic sourcing requirements. Taxpayers who may bear costs if the biomanufacturing strategic reserve study leads to a funded reserve program. Federal agency staff who would bear the administrative burden of staffing and supporting the new subcommittee and producing the required report.
Supporters argue
Supporters argue that the Defense Production Act Committee currently lacks a dedicated mechanism to assess how fast-moving technologies like AI, quantum computing, and biotechnology affect national defense readiness and supply chain resilience. They contend that the COVID-19 pandemic exposed dangerous gaps in domestic biomanufacturing capacity, and that a formal subcommittee with a mandate to study these issues — and report to Congress — is a necessary first step toward closing those vulnerabilities before a future crisis.
Opponents argue
Opponents argue that the bill creates a new layer of federal bureaucracy — a subcommittee tasked with studying problems that existing agencies such as the Department of Defense, DARPA, and the Commerce Department already analyze. They contend that without dedicated funding, enforcement authority, or binding recommendations, the subcommittee and its required report may produce little actionable change, making this an exercise in process rather than a meaningful improvement to national defense preparedness.
Constitutional context
The Defense Production Act rests on Congress's authority under the Commerce Clause (Art. I, §8, cl. 3) and its war and national defense powers. This bill modifies an existing committee structure and mandates a study report — it does not delegate broad new rulemaking authority to an agency, so the major questions doctrine (West Virginia v. EPA, 2022) and post-Chevron scrutiny (Loper Bright, 2024) are not directly implicated.
Checks and balances
The executive branch gains a new internal coordination body, but Congress retains oversight through the mandatory report requirement and the bill's placement within the existing Defense Production Act framework, which is subject to congressional reauthorization.
Historical precedent
The Defense Production Act has been amended multiple times to add oversight bodies and reporting requirements, including the establishment of the Committee on Foreign Investment in the United States (CFIUS) and various supply chain review mandates following post-9/11 and COVID-era security concerns.